compounds mediate their effects by targeting Hsp-90. The anticancer potential of the allyl amino derivative of geldanamycin is currently being evaluated in phase I clinical trials. Drs Joseph A Fontana and Arun K Rishi review the molecular mechanisms of classical and novel retinoids in context to cancer therapy. They discuss, in detail, the synthetic retinoids 4-HPR and CD437 and their potential therapeutic efficacies in the treatment of various malignant diseases. Several molecules serving as potential molecular targets of these retinoids are also listed in their article.
Newer and state-of-the-art tools are needed in the discovery and validation of molecular targets. In their article, Drs Michael S Orr and Uwe Scherf describe the utility and progress of gene chip microarray approaches in the discovery and validation of molecular drug targets. They also highlight the difficulties that still exist in the pursuit of such goals. Unlike DNA microarray analyses, expression proteomics seeks to explore global alterations in protein expression. Significant efforts and resources have been invested by academia and the pharmaceutical industry in the development and application of proteomics tools. In the article by Dr Samir M Hanash and colleagues, the emerging field of proteomics and its utility in discovering molecular targets have been discussed.
The article by Drs John T Lee Jr and James A McCubrey focuses on the Raf/MEK/ERK signaling cascade. In particular, the authors discuss different approaches to target various components of this potentially important signaling cascade for therapeutic interventions. Dr Linda Z Penn and colleagues describe statin family of drugs in their article. Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and have been reported to exhibit higher tumoricidal activity than the non-transformed cells. Statins appear to mediate their anticancer effects by inducing apoptosis and their apoptotic effects occur, at least in part, via cellular depletion of geranylgeranyl pyrophosphate (GGPP). Additional in-depth studies are, however, needed to further illuminate the exact molecular mechanisms by which statins mediate their anticancer effects (an original article by Dr AC Bloem and colleagues describing lovastatin-induced apoptosis in myeloma plasma cells will be published in a subsequent issue). In their article, Drs Manish Monga and Edward A Sausville give an overview of the 'Developmental Therapeutics Program at the National Cancer Institute, USA' and its role in molecular target and drug discovery. Their article also lists various reagents and free services available to the extramural scientific community interested in molecular target and drug discovery. Myeloid Differentiation (MyD) and Growth Arrest and DNA Damageinducible (GADD) genes encode a group of proteins that are involved in differentiation and cellular stress response. In their article, Drs Dan A Liebermann and Barbara Hoffman discuss the MyD/GADD gene products as possible targets for cancer therapy.
This Spotlight will continue to feature review articles on different and important topics from this emerging area of 
